References
- U.S. Food and Drug Administration. FDA approves Viibryd to treat major depressive disorder. FDA News Release [Internet]. 2011 Jan 21; Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm240642.htm.
- Allergan Pharmaceuticals International Limited. Viibryd (R) [Package Insert]. Irvine, CA; 2017.
- Bartoszyk GD, Hegenbart R, Ziegler H. EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT(1A) receptor agonistic properties. Eur J Pharmacol. 1997;322:147–153.
- U.S. Food and Drug Administration. Clinical Pharmacology and Biopharmaceutics Review [Internet]. 2010. Available from: http://www.accessdata.fda.gov/drugsatfda_%0Adocs/nda/2011/022567Orig1s000ClinPharmR.pdf
- Gazewood J, Slayton P, DeGeorge K. Vilazodone (Viibryd) for the treatment of depression. Am Fam Physician. 2013;88:263–264.
- McCormack PL. Vilazodone: a review in major depressive disorder in adults. Drugs. 2015;75:1915–1923.
- Durgam S, Gommoll C, Forero G, et al. Efficacy and safety of vilazodone in patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled, flexible-dose trial. J Clin Psychiatry. 2016;77:1687–1694.
- Singh M, Schwartz TL. Clinical utility of vilazodone for the treatment of adults with major depressive disorder and theoretical implications for future clinical use. Neuropsychiatr Dis Treat. 2012;8:123–130.
- Nelson LS, Erdman AR, Booze LL, et al. Selective serotonin reuptake inhibitor poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2007;45:315–332.
- Klein-Schwartz W, Benson BE, Lee SC, et al. Comparison of citalopram and other selective serotonin reuptake inhibitor ingestions in children. Clin Toxicol. 2012;50:418–423.
- Carstairs SD, Griffith EA, Alayin T, et al. Recurrent seizure activity in a child after acute vilazodone ingestion. Ann Emerg Med. 2012;60:819–820.
- Acker EC, Sinclair EA, Beardsley AL, et al. Acute vilazodone toxicity in a pediatric patient. J Emerg Med. 2015;49:284–286.
- Russell JL, Spiller HA, Chounthirath T, et al. Pediatric ingestion of vilazodone compared to other selective serotonin reuptake inhibitor medications. Clin Toxicol. 2017;55:352–356.
- American Association of Poison Control Centers. National Poison Data System (NPDS): NPDS Coding Users’ Manual, Version 3.1. 2014.
- Wolkin AF, Martin CA, Law RK, et al. Using poison center data for national public health surveillance for chemical and poison exposure and associated illness. Ann Emerg Med. 2012;59:56–61.
- Beuhler MC, Spiller HA, Sasser HC. The outcome of unintentional pediatric bupropion ingestions: a NPDS database review. J Med Toxicol. 2010;6:4–8.
- Ables AZ, Nagubilli R. Prevention, recognition, and management of serotonin syndrome. Am Fam Physician. 2010;81:1139–1142.
- Boyer E. The serotonin syndrome. N Engl J Med. 2005;352:1112.
- Gill M, LoVecchio F, Selden B. Serotonin syndrome in a child after a single dose of fluvoxamine. Ann Emerg Med. 1999;33:457–459.
- Phan H, Casavant MJ, Crockett S, et al. Serotonin syndrome following a single 50 mg dose of sertraline in a child. Clin Toxicol. 2008;46:845–849.
- Ma J, Lee K, Stafford RS. Depression treatment during outpatient visits by U.S. children and adolescents. J Adolesc Heal. 2005;37:434–442.
- Czaja AS, Valuck R. Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence. Pharmacoepidemiol Drug Saf. 2012;21:997–1004.
- Centers for Medicare and Medicaid Services. Antidepressant medications: use in pediatric patients [Internet]. 2015; [cited 2017 Apr]. Available from: https://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/Medicaid-Integrity-Education/Pharmacy-Education-Materials/Downloads/ad-pediatric-factsheet11-14.pdf